Deichmann, R., Lavie, C., & Andrews, S
(100) demonstrated decreased 24-hour GH secretion despite the mean IGF-I SDS being +1.0 in patients with Cushings disease, and Bang et al
Gastric emptying delay (primary mechanism) Most powerful effect of amylin: Dramatically slows stomach emptying Food stays in stomach 2-3x longer than normal Creates mechanical fullness sensation Strongest gastric slowing of any hormone/drug class Mechanism of gastric slowing: Amylin receptors on stomach smooth muscle Reduces stomach contractions (peristalsis) Slows pyloric sphincter opening (stomach intestine) Extends digestive process significantly Gastric emptying comparison: Why this matters for weight loss: Mechanical fullness = can't eat large portions Extended satiety = skip snacks naturally Naturally eat less without hunger Cumulative calorie deficit over time Potential downside: Too much slowing = gastroparesis (pathological delay) Nausea from prolonged fullness Constipation (entire GI tract slows) Why titration is critical Central appetite suppression (brainstem) Direct brain effects: Amylin crosses blood-brain barrier Acts on area postrema (brainstem) Also affects nucleus accumbens Different pathways than GLP-1 Area postrema role: "Vomiting center" of brain Also integrates satiety signals Direct feeding behavior control Why nausea is common side effect (overstimulation) Amylin vs GLP-1 appetite pathways: Why different pathways matter: GLP-1 primarily hypothalamus (arcuate nucleus) Amylin primarily brainstem (area postrema) Combining = two different appetite suppression mechanisms Synergistic not redundant Explains CagriSema's superior results Glucagon suppression and glucose regulation Amylin's metabolic effects: Suppresses postprandial glucagon secretion Glucagon normally raises blood glucose Inhibiting glucagon = better glucose control Reduces hepatic glucose output Why this helps weight loss: Better glucose control = less insulin spikes Lower insulin = less fat storage signaling Reduced postprandial glucose = less hunger rebound Metabolic optimization Diabetes benefits (primary FDA indication for pramlintide): Complements insulin therapy Reduces mealtime glucose spikes Lowers HbA1c (long-term glucose marker) Originally developed for diabetes, not obesity Weight loss as secondary benefit: Diabetes patients on pramlintide lost modest weight Led to investigation of amylin for obesity Cagrilintide developed specifically for weight loss Higher doses than needed for glucose alone Meal frequency and portion size reduction Real-world eating behavior changes: Meal frequency: Normal: 5-6 eating occasions daily (3 meals + snacks) On amylin agonists: 3-4 eating occasions (meals only, skip snacks) Natural reduction without conscious effort Extended satiety eliminates snacking urge Portion sizes: Normal: 500-800 calorie meals common On amylin agonists: 300-500 calorie meals typical Physical fullness limits consumption Can't finish normal portions Example calorie reduction: Baseline: 2,500 calories daily On amylin agonist: 1,500-1,800 calories daily Deficit: 700-1,000 calories daily Weekly deficit: 4,900-7,000 calories (1.4-2 lbs loss/week) No conscious restriction needed: Not "willpower" or "dieting" Physiological appetite suppression Eating to comfortable fullness (just reduced capacity) Sustainable long-term See our best peptides for weight loss , best peptide stack for weight loss , and peptides for fat loss
- GHK-Cu 100 mg, 3ml - Mots-c 15, 1,6ml Retatrutide Pen 20 mg
Ipamorelin appears to stand out from other GHSs as a potentially more selective compound, which may possibly stimulate the release of GH levels by somatotroph cells without also increasing other hormones produced by the anterior pituitary gland, such as prolactin
Most early side effects trace back to not drinking enough
